SCHEMBL4696868

SCHEMBL4696868

Cc1cc(OCCN(C)C)c(C(C)C)cc1OC(=O)COCC(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 2/20 0.71
ADRA1A P35348 2/20 0.71
ADRA1B P35368 2/20 0.71
CYP1A2 P05177 1/20 0.71
ADRA2A P08913 1/20 0.71
CYP2D6 P10635 1/20 0.71
PKM P14618 1/20 0.71
ADRA2B P18089 1/20 0.71
ADRA2C P18825 1/20 0.71
HTR2C P28335 1/20 0.71
HRH1 P35367 1/20 0.71
DRD3 P35462 1/20 0.71
OPRK1 P41145 1/20 0.71
CHRNA4 P43681 1/20 0.71
HIF1A Q16665 1/20 0.71
SMN1; SMN2 Q16637 4/20 0.69
BLM P54132 1/20 0.69
KDM4E B2RXH2 11/20 0.53
ALDH1A1 P00352 10/20 0.53
TDP1 Q9NUW8 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693925 0.86 HRH1 (0.61) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
SCHEMBL4697853 0.84 ADRA1D (0.71) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
Moxisylyte SCHEMBL456546 0.83 ADRA1D (1.00) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
SCHEMBL4696872 0.82 CYP1A2 (0.47) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
Moxisylyte SCHEMBL317080 0.82 SMN1; SMN2 (1.00) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
Moxisylyte SCHEMBL1649830 0.81 ADRA1D (0.95) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
SCHEMBL5235884 0.81 ADRA1D (0.72) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
Iproxamine SCHEMBL1815834 0.80 ADRA1D (0.76) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
SCHEMBL4695767 0.80 ADRA1D (0.71) ADRA1DADRA1AADRA1BCYP1A2ADRA2A
SCHEMBL5236595 0.80 ADRA1D (0.71) ADRA1DADRA1AADRA1BCYP1A2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109542-A4 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-03-26 EP disclosed
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds NITROMED, INC. (US) 2005-08-25 US disclosed
US-6469065-B1 COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE NITROMED, INC. 2002-10-22 US disclosed
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use GARVEY DAVID S (US) 2002-10-03 US disclosed
EP-1109542-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-06-27 EP disclosed
WO-2000012075-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds ADRB1, ADRB3, ADRA1D ADRA1D 3/4885ADRA1A 5/4885ADRA1B 8/4885
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use ADRB1, ADRB3, ADRA1D ADRA1D 3/4885ADRA1A 8/4885ADRA1B 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.